Novo Nordisk Vs Eli Lilly Stock

last updated on

Novo Nordisk Vs Eli Lilly Stock

Novo Nordisk Vs. Eli Lilly: Which Stock To Buy?

Novo Nordisk and Eli Lilly are two big names in the pharma sector. They are both famous for their GLP-1 businesses and are leaders in the weight loss niche.

The recent results of Eli Lilly were good and impressed the investors. On the other hand, the results of Novo Nordisk were not good, and the company is still at a loss.

Eli Lilly And Novo Nordisk Are Leaders In GLP-1 Market

Amidst all of this, should you buy Novo Nordisk or Eli Lilly? Let's take a closer look at both of these pharma companies.

Eli Lilly makes Mounjaro for diabetes. Meanwhile, Zepbound is for weight management. On the other hand, Novo Nordisk makes Ozempic and Wegovy. The data shows that drugs from Eli Lilly are much better for chronic weight management as compared to Novo Nordisk.

In Q2, the revenue of Zepbound was $4.9 billion with a 46% y/y increase. The sales of Wegovy are only up by 1% y/y. So, it's clear that Eli Lilly is set to make more revenue than Novo Nordisk.

A quick look at the pipelines of both firms shows Eli Lilly is way ahead. Eli Lilly is working on Retatrutide, a new weight-loss medicine that will be more effective than Zepbound.

However, Novo Nordisk still has teh edge when we talk about the oral weight loss market because of Wegovy. But when we look at the overall GLP-1 market, Eli Lilly is still on top.

The portfolio of Eli Lilly is also more diversified and has several big-name products. Eli Lilly is also working on newer products that could easily generate more than $1 billion in annual sales.

With all things considered, Eli Lilly stock is the better option as compared to Novo Nordisk. Its future revenue and earnings are expected to be way higher than Novo Nordisk's. So, if you want to capitalize on the GLP-1 trend, go with Eli Lilly stock.

Trending Stories